← Issue №19/ week of Nov 8, 2026/ the whole section, in full

Endoscopy, in full.

All 8 Endoscopy papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 8, in full

most clinically useful first · the 1 the issue led with is ruled in green
Endoscopy prospective cohort · n=172,875 · Nov 5, 2026 · Clin Gastro Hep · IF 16.2

Risk of post-colonoscopy colorectal cancer according to colonoscopy quality and polyp findings.

New evidencecolonoscopypolypectomyendoscopy qualitycolorectal cancer screening
Clinical takeawayEnsure adenoma detection rates (ADR) meet or exceed ≥30% in women and ≥40% in men to reduce PCCRC risk.
What it foundIncreasing ADR to ≥30% in women and ≥40% in men could prevent 46% of PCCRC cases (95%CI, 27-76%) compared to lower ADR thresholds.
ContextConfirms the critical role of ADR in PCCRC prevention and extends evidence by quantifying the joint impact of ADR and polyp findings, highlighting the importance of optimizing colonoscopy quality.
Measured against the standard of care· USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. For serrated polyps: 1-2 SSLs <10 mm, 5-10 years; 3-4 SSLs <10 mm or a hyperplastic polyp ≥10 mm, 3-5 years; an SSL ≥10 mm, an SSL with dysplasia, or a traditional serrated adenoma, 3 years. When findings are mixed, use the shortest interval indicated. Before applying an interval, confirm complete resection and adequate prep. Piecemeal resections get a site check, and malignant (T1) polyps go to a tumor-board pathway. Serrated polyposis syndrome (SPS) is now governed by a separate USMSTF consensus statement (Rex et al., published simultaneously in Gastroenterology, Am J Gastroenterol and GIE on 2026-09-30). It has 11 recommendations. Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. SPS colonoscopy should be done by endoscopists with documented adequate SSL detection, using high-definition white light with or without chromoendoscopy. Without concurrent CRC, endoscopy is preferred over surgery for primary management. If the polyp burden cannot be managed endoscopically, refer to an advanced endoscopic resection expert before surgery. Resect SSLs and hyperplastic polyps by cold snare, with submucosal injection for larger lesions. Do clearance colonoscopy at 3-6 months, then surveil every 1-2 years. Consider 3-year intervals if the burden is greatly reduced at surveillance. First-degree relatives start colonoscopy at age 40, or 10 years before the youngest CRC diagnosis in the family, or 5 years before the youngest SPS diagnosis, whichever comes first. SPS has no established genetic basis, so germline testing is recommended only when concurrent non-serrated polyps suggest a heritable syndrome. Lynch, FAP/AFAP and MAP criteria still trigger genetic evaluation.

USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement) · reviewed 2026-10-11 ↗
Chen Y … Song M · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Endoscopy retrospective · n=5,028 · Nov 2, 2026 · J Clin Gastro · IF 2.9

Percutaneous Endoscopic Gastrostomy Versus Image-Guided Gastrostomy Placement in Patients With Cirrhosis: A Multi-Institutional Research Network Study.

Practice-changingcirrhosishealth services
Clinical takeawayWhere both routes suit the patient, these associations favour PEG; this is a retrospective propensity-matched cohort, so the mortality difference is an association.
What it foundPEG placement in cirrhosis patients was associated with reduced 6-month mortality (aHR 0.80, 95% CI 0.70-0.91) and fewer tube replacements (aOR 0.47, 95% CI 0.36-0.63) compared to IR G-tube.
ContextProvides evidence to inform gastrostomy tube selection in cirrhosis patients.
Refinessuggested applicable standard· ASGE 2024 (Gastrointest Endosc 2025;101:25-35) / ESGE 2021 (Endoscopy 2021;53:178-195)

PEG remains the standard for durable enteral access in patients unable to swallow safely or meet nutritional needs orally, placed by the pull (Gauderer-Ponsky) technique, and ASGE 2024 now suggests PEG over IR-guided gastrostomy for initial placement in normal foregut anatomy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

PEG remains the standard for durable enteral access in patients unable to swallow safely or meet nutritional needs orally, placed by the pull (Gauderer-Ponsky) technique, and ASGE 2024 now suggests PEG over IR-guided gastrostomy for initial placement in normal foregut anatomy. A single prophylactic IV dose of a beta-lactam antibiotic (e.g., cefazolin) is given before placement. Post-procedure bowel rest is no longer recommended: feeding may start within 3-4 hours of uncomplicated placement (ESGE 2021, strong/high-quality; ASGE 2024, strong/moderate), medications may be given immediately, and routine gastric residual volume checks are not indicated. Buried bumper prophylaxis is daily site care with DAILY inward tube mobilization and a loose external bumper kept 1-2 cm from the abdominal wall (ESGE 2021), not weekly rotation. Antiplatelet agents, including dual antiplatelet therapy, need not be routinely withheld for PEG; anticoagulant management is individualized by multidisciplinary discussion of bleeding versus thrombotic risk. In malignant dysphagia, either transoral pull PEG or direct (introducer) PEG is acceptable with counseling about implantation metastasis and periodic site examination. Device selection among PEG, PEG-J, DPEJ, surgical gastrostomy, and parenteral nutrition remains multidisciplinary, and a goals-of-care discussion before placement, including avoiding routine PEG in advanced dementia in favor of careful hand feeding (AGA 2020 / Choosing Wisely), is unchanged.

ASGE 2024 (Gastrointest Endosc 2025;101:25-35) / ESGE 2021 (Endoscopy 2021;53:178-195) · reviewed 2026-07-19 ↗
Cooper KM … Kohli DR · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy retrospective · n=192 · Nov 5, 2026 · GIE · IF 8.0

Safety and Outcomes of EUS-Guided Choledochoduodenostomy in Patients with a Common Bile Duct Diameter ≤15 mm.

New evidenceEUSERCPbiliary strictureendoscopy quality
Clinical takeawayAfter failed ERCP in ducts ≤15 mm, expect about a 10% misdeployment risk; two-step deployment had fewer misdeployments unadjusted (3.3% vs 13.7%) but not significantly after adjustment, and duodenal obstruction predicted later stent dysfunction.
What it foundEUS-CDS in bile ducts ≤15 mm achieved 91.7% technical success and 90.1% clinical success, with a 10.4% stent misdeployment rate.
ContextConfirms EUS-CDS feasibility in bile ducts ≤15 mm but identifies specific risks and mitigation strategies, primarily in patients with malignant biliary obstruction.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

… For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. … High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. … Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Srivastava R … Khashab MA · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy retrospective · n=402 · Nov 2, 2026 · Diseases of the Esophagus · IF 2.5

Lessons learned from a decade of EUS(-FNA) staging in esophageal and GEJ carcinoma: towards a selective staging strategy.

New evidenceesophageal cancerEUS
Clinical takeawayConsider EUS-FNA selectively in esophageal or GEJ carcinoma patients planned for neoadjuvant or definitive chemoradiotherapy (CRT), particularly in squamous cell carcinoma or FDG-PET non-suspicious cases, as it may modify the radiation field. Avoid routine EUS-FNA in patients planned for perioperative FLOT followed by surgical lymphadenectomy, as most involved LN stations are routinely addressed surgically.
What it foundEUS-FNA altered the radiation field in 8.7% of patients (4.5% expansion, 4.2% reduction) compared to FDG-PET staging.
ContextChallenges the routine use of EUS-FNA in all esophageal or GEJ carcinoma patients, highlighting its selective utility in CRT planning and limited added value in FLOT-treated patients.
Refinessuggested applicable standard· National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Esophageal and Esophagogastric Junction Cancers, Version 2.2023 (peer-reviewed publication; medically-unfit-vs-fit pathway split confirmed unchanged in current Version 3.2025)

… PRIMARY TREATMENT, MEDICALLY FIT PATIENTS, ADENOCARCINOMA (ESOPH-13): cT1b-cT2, N0 LOW-RISK (<3 cm, well differentiated) → esophagectomy. cT2 N0 HIGH-RISK (LVI, ≥3 cm, or poorly differentiated), cT1b-cT2 N+, or cT3-cT4a any N → perioperative systemic therapy is PREFERRED (FLOT: 5-FU 2600 mg/m2 IV over 24 h day 1, leucovorin 200 mg/m2, oxaliplatin 85 mg/m2, docetaxel 50 mg/m2, every 14 days, 4 cycles pre- and 4 cycles postoperatively; or FLOT + durvalumab 1500 mg for PD-L1 CPS ≥1 or TAP ≥1%, category 1 for EGJ, category 2A for esophageal adenocarcinoma; note MATTERHORN showed no EFS advantage for durvalumab in diffuse-type disease), QUALIFIER: perioperative therapy is preferred for patients medically fit and with access to frequent toxicity evaluation; preoperative chemoradiation for planned esophagectomy remains an option and may be considered for borderline-resectable patients or patients who are not FLOT candidates (perioperative FOLFOX/CAPOX is another alternative). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes WORKUP (NCCN ESOPH-1), BIOMARKERS, POSTOPERATIVE (ESOPH-F) and 2 more.

Our full summary of this standard

WORKUP (NCCN ESOPH-1): H&P; EGD with biopsy; chest/abdomen CT with oral and IV contrast; pelvis CT with contrast ONLY as clinically indicated; FDG-PET/CT (skull base to mid-thigh) if no evidence of M1 disease; CBC and comprehensive chemistry; EUS if no evidence of M1 or unresectable disease; endoscopic resection (ER) is recommended for accurate staging of early-stage cancers (Tis, T1a, or T1b) and may also be therapeutic; bronchoscopy if the tumor is at or above the carina with no evidence of M1; biopsy of metastatic disease as clinically indicated; assign Siewert category; nutritional assessment and counseling; smoking-cessation counseling; screen for family history. BIOMARKERS: universal MSI (PCR/NGS) or MMR (IHC) testing AND universal PD-L1 testing in ALL newly diagnosed patients; HER2 and CLDN18.2 testing if advanced/metastatic adenocarcinoma is documented or suspected; NGS should be considered. Multidisciplinary evaluation is recommended for stage I-IVA (locoregional) disease (ESOPH-E). ENDOSCOPIC THERAPY (ESOPH-A): the goal of endoscopic therapy (EMR, ESD, and/or ablation) is complete removal or eradication of early-stage disease, pTis, pT1a, and SELECTED superficial pT1b without LVI, plus the pre-neoplastic Barrett's segment. Tis/HGD must first be fully characterized for nodularity, lateral spread and multifocality, with EUS to rule out nodal metastases in select higher-risk cases. Areas of nodularity or ulceration must be RESECTED, not ablated. Completely flat lesions ≤2 cm (squamous HGD/Tis, and BE with flat HGD) should be treated by ER because it gives more accurate histologic assessment; flat lesions >2 cm can be treated by ER but with greater complication risk, and may be treated by ablation alone (data for ablation-alone in squamous HGD are very limited). Lesions pathologically limited to lamina propria/muscularis mucosae (pT1a) or superficial submucosa (pT1b), in the absence of nodal metastases, LVI, or poor differentiation, can be treated with full ER, HOWEVER a thorough patient-and-surgeon discussion of esophagectomy versus the risk of concurrent nodal disease should be undertaken, especially for larger tumors or deeper invasion. Ablation of residual Barrett's should follow ER; complete BE eradication may also be achieved by widefield EMR or ESD at the initial intervention when needed to resect superficial tumor or nodularity ≤2 cm. For SCC, the level of evidence for ablation after ER is LOW; additional ablation may be needed only for multifocal HGD/CIS elsewhere, and may not be needed for completely excised lesions. Endoscopic therapy is 'PREFERRED' for limited early-stage disease: Tis and T1a, ≤2 cm, well or moderately differentiated. Esophagectomy is indicated for extensive carcinoma in situ (pTis/HGD), pT1a, or superficial pT1b, especially nodular disease not adequately controlled endoscopically. PRIMARY TREATMENT, MEDICALLY FIT PATIENTS, ADENOCARCINOMA (ESOPH-13): cT1b-cT2, N0 LOW-RISK (<3 cm, well differentiated) → esophagectomy. cT2 N0 HIGH-RISK (LVI, ≥3 cm, or poorly differentiated), cT1b-cT2 N+, or cT3-cT4a any N → perioperative systemic therapy is PREFERRED (FLOT: 5-FU 2600 mg/m2 IV over 24 h day 1, leucovorin 200 mg/m2, oxaliplatin 85 mg/m2, docetaxel 50 mg/m2, every 14 days, 4 cycles pre- and 4 cycles postoperatively; or FLOT + durvalumab 1500 mg for PD-L1 CPS ≥1 or TAP ≥1%, category 1 for EGJ, category 2A for esophageal adenocarcinoma; note MATTERHORN showed no EFS advantage for durvalumab in diffuse-type disease), QUALIFIER: perioperative therapy is preferred for patients medically fit and with access to frequent toxicity evaluation; preoperative chemoradiation for planned esophagectomy remains an option and may be considered for borderline-resectable patients or patients who are not FLOT candidates (perioperative FOLFOX/CAPOX is another alternative). Consider neoadjuvant or perioperative immune checkpoint inhibitor if the tumor is MSI-H/dMMR (in multidisciplinary consultation; the role of surgery after complete response is unclear). Definitive chemoradiation for patients who are medically unfit/inoperable for surgery or who decline surgery. cT4b → definitive chemoradiation, or chemotherapy alone with invasion of trachea, great vessels, vertebral body, or heart. SQUAMOUS CELL CARCINOMA (ESOPH-2): cT1b-cT2, N0 LOW-RISK (<3 cm, well differentiated) → esophagectomy (non-cervical esophagus). cT2 N0 high-risk (LVI, ≥3 cm, poorly differentiated), cT1b-cT2 N+, or cT3-cT4a any N → PREOPERATIVE CHEMORADIATION is preferred (or definitive chemoradiation). cT4b → definitive chemoradiation, or chemotherapy alone for trachea/great-vessel/vertebral/cardiac invasion. NCCN states explicitly: 'Preoperative chemoradiation is preferred for esophageal SCC.' Preoperative RT dose 41.4-50.4 Gy at 1.8-2.0 Gy/day (23-28 fractions); preferred concurrent regimens include weekly paclitaxel 50 mg/m2 + carboplatin AUC 2 (CROSS, category 1) and fluorouracil + oxaliplatin (category 1). POSTOPERATIVE (ESOPH-F): nivolumab is the preferred postoperative regimen ONLY after PREOPERATIVE CHEMORADIATION with R0 resection and residual pathologic disease (category 1), 240 mg IV every 14 days for 16 weeks, then 480 mg IV every 28 days, maximum treatment duration 1 year. PALLIATION (ESOPH-A/H): esophageal dilation with balloons or bougies for temporary relief of malignant or treatment-related obstruction (avoid overdilation, perforation risk); long-term dysphagia palliation by endoscopic tumor ablation (Nd:YAG laser, PDT, cryoablation) or expandable metal/plastic stents; feeding gastrostomy or jejunostomy for anorexia/dysphagia/malnutrition, but placement of a GASTROSTOMY preoperatively may compromise the gastric vasculature and interfere with gastric-conduit reconstruction and SHOULD BE AVOIDED (feeding jejunostomy is generally preferred for postoperative nutritional support; multidisciplinary expertise is recommended before percutaneous gastrostomy).

National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Esophageal and Esophagogastric Junction Cancers, Version 2.2023 (peer-reviewed publication; medically-unfit-vs-fit pathway split confirmed unchanged in current Version 3.2025) · reviewed 2026-07-23 ↗
Quik JSE … IJspeert JEG · Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus · IF 2.5 · PubMed ↗Permalink
Endoscopy retrospective · n=492 · Nov 2, 2026 · Endoscopy · IF 11.8

Efficacy of Endoscopic Hand Suturing for Prevention of Adverse Events After Gastric Endoscopic Submucosal Dissection: A Multicenter Propensity Score-Matched Study.

New evidenceESDhemostasisendoscopy qualitycomputer-aided detection
Clinical takeawayWhere hand suturing is available, consider closing gastric ESD defects, allowing a median 52.5 minutes and a learning curve of about 25 cases; the evidence is retrospective with historical controls.
What it foundIn a retrospective propensity-matched study (123 sutured vs 369 historical and contemporaneous controls), adverse events were 1.6% vs 8.9% and delayed bleeding 1.6% vs 8.4%. Closure was complete in 94.7%, median suturing time 52.5 minutes; 27% dehisced by day 5 without more delayed bleeding.
ContextLarger absolute risk reductions in BEST-J high and very-high risk groups were exploratory.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Minoda Y … Okamura T · Endoscopy · IF 11.8 · PubMed ↗Permalink
Endoscopy retrospective · n=292 · Nov 6, 2026 · J Hepatobil Pancreat Sci · IF 3.8

Association Between Concomitant Gallstones and Late Biliary Adverse Events After Endoscopic Papillectomy.

New evidencecholedocholithiasisERCPendoscopy qualitybiliary stricture
Clinical takeawayTreat concomitant gallstones as a risk marker for late biliary events after endoscopic papillectomy when counselling patients and planning follow-up.
What it foundPatients with gallstones had a 25.9% rate of late adverse events after endoscopic papillectomy vs 10.5% without gallstones (aHR 2.97, 95% CI 1.53-5.75), with a 1-year cumulative incidence of 23.2% vs 5.7%.
ContextRetrospective series of 292 patients with intact gallbladders; the association held for biliary but not pancreatic events.
Measured against the standard of care· AGA Clinical Practice Update (Expert Review) 2026 / ESGE 2021

Decision at stakethe risk stratification for late biliary adverse events after endoscopic papillectomy

… DIAGNOSIS: both use a side-viewing duodenoscope. AGA adds that biopsies should avoid the pancreatic orifice to limit post-procedure pancreatitis. Because 20-40% of ampullary adenomas harbor malignancy, AGA advises AT LEAST 6 biopsies, targeting ulcerated or indurated areas. ESGE requires proven adenoma before papillectomy and recommends against diagnostic papillectomy. … TECHNIQUE: both say to avoid biliary or pancreatic sphincterotomy before papillectomy (AGA's reasons: cautery artifact and bleeding) and to use en bloc snare resection when feasible. Submucosal injection is generally not needed, except for a laterally spreading duodenal-wall component. ESGE also suggests endocut current. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes STAGING, SELECTION, PANCREATITIS PROPHYLAXIS and 4 more.

Our full summary of this standard

Two current documents govern ampullary adenoma: the AGA Clinical Practice Update expert review (Barakat, Maranki, Irani, Chahal; Clin Gastroenterol Hepatol, online 2026-09-09; ungraded Best Practice Advice from literature review plus expert opinion, no systematic review) and the ESGE 2021 graded guideline (Vanbiervliet et al., Endoscopy 2021;53:429-448), which it does not replace. DIAGNOSIS: both use a side-viewing duodenoscope. AGA adds that biopsies should avoid the pancreatic orifice to limit post-procedure pancreatitis. Because 20-40% of ampullary adenomas harbor malignancy, AGA advises AT LEAST 6 biopsies, targeting ulcerated or indurated areas. ESGE requires proven adenoma before papillectomy and recommends against diagnostic papillectomy. STAGING: AGA says to consider EUS for every adenoma potentially amenable to endoscopic resection, EXCEPT lesions <1 cm with no worrisome clinical or endoscopic features. ESGE recommends EUS plus MRCP (IDUS in selected patients) and advises against routine molecular testing of biopsies. SELECTION: AGA describes the lesion most amenable to papillectomy as having well-defined margins, size <4-5 cm, nonfriable tissue, softness to probing, and intraductal extension <=1 cm. AGA sets 3 absolute contraindications: metastatic spread; invasive cancer beyond the mucosa; and >1 cm intraductal extension in a surgically fit patient. Relative contraindications are size >5 cm, early-stage/T1 cancer, and likely poor follow-up adherence. For >1 cm intraductal extension, AGA suggests surgical consultation; <1 cm may be treated endoscopically with close surveillance. This is a stricter intraductal threshold than ESGE's, which suggests surgery only for intraductal involvement >20 mm and adjunct RFA or cystotome ablation with temporary biliary stenting for <=20 mm in expert centers. ESGE also gates en bloc resection at adenomas up to 20-30 mm and lists >4 cm or a periampullary diverticulum as technical reasons to consider surgery. TECHNIQUE: both say to avoid biliary or pancreatic sphincterotomy before papillectomy (AGA's reasons: cautery artifact and bleeding) and to use en bloc snare resection when feasible. Submucosal injection is generally not needed, except for a laterally spreading duodenal-wall component. ESGE also suggests endocut current. PANCREATITIS PROPHYLAXIS: AGA advises using ALL THREE together: prophylactic pancreatic duct stent, rectal NSAID, and high-volume lactated Ringer's. ESGE recommends the PD stent and rectal diclofenac or indomethacin 100 mg, with lactated Ringer's suggested mainly when stenting is not possible. BLEEDING: standard hemostasis methods (epinephrine, electrocoagulation, clips, APC, hemostatic sprays); ESGE says prophylactic hemostasis is individualized. BILIARY DRAINAGE when resection is not feasible: AGA allows drainage with or without sphincterotomy and SEMS for significant jaundice or cholangitis, at the surgeon's discretion. ESGE recommends against routine preoperative drainage, reserving it for cholangitis, severe jaundice, delayed surgery, or neoadjuvant therapy, with SEMS when drainage is needed. ADJUNCT/RESIDUAL: for adenomas >3 cm resected piecemeal or with positive margins, AGA advises considering adjunct thermal ablation plus ductography, repeated every 2-3 months until biopsy confirms eradication. ESGE allows APC and EMR for benign residual or recurrent lesions. SURVEILLANCE: both use the same schedule: side-viewing duodenoscopy with biopsy of the scar and any abnormal area at 3 months, then at 6 and 12 months, then yearly for at least 5 years. AGA says surveillance beyond 5 years should be individualized (recurrence risk, comorbidity, life expectancy) but is required if high-risk features are present. In FAP, AGA individualizes intervals by ampullary, gastric and duodenal disease burden. MALIGNANCY: AGA advises multidisciplinary discussion (GI, surgery, oncology) for high-grade dysplasia, incomplete resection, or suspected malignancy. ESGE recommends pancreaticoduodenectomy with lymphadenectomy for T1 or higher, and accepts local resection for Tis when final pathology shows no residual disease.

AGA Clinical Practice Update (Expert Review) 2026 / ESGE 2021 · reviewed 2026-10-11 ↗
Takada Y … Kawashima H · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Endoscopy prospective cohort · Nov 4, 2026 · Endoscopy · IF 11.8

Declining Cost-Effectiveness of Gastric Cancer Screening Over a Decade: A Cohort Modelling Study.

Epidemiologycost-effectivenessepidemiologyhealth servicescolorectal cancer screening
Clinical takeawayNo change for individual practice: a model of Korea's national programme that supports periodic reassessment of mature screening programmes and evaluation of differentiated approaches.
What it foundThe incremental cost-utility ratio (ICUR) for biennial endoscopic gastric cancer screening in Korea increased from KRW 9.62 million/QALY (USD 7,694) in 2012 to KRW 48.62 million/QALY (USD 38,895) in 2022, with women showing a higher ICUR (KRW 84.37 million/QALY, USD 67,497) than men (KRW 28.20 million/QALY, USD 22,558).
ContextThis literature reports a declining cost-effectiveness of gastric cancer screening over a decade, as evidenced by cohort modelling studies.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Nam KA … Park JM · Endoscopy · IF 11.8 · PubMed ↗Permalink
Endoscopy retrospective · n=107 · Nov 2, 2026 · Diseases of the Esophagus · IF 2.5

Esophageal squamous papillomas.

New evidenceesophageal cancerepidemiology
Clinical takeawayTreat an isolated non-dysplastic squamous papilloma as a minor finding, but assess the wider mucosa and patient-level risk factors before dismissing it; the cohort's follow-up rate was low.
What it foundNo dysplasia found in 107 adults with esophageal squamous papilloma (ESP) at index endoscopy, with one synchronous squamous cell carcinoma and no metachronous dysplasia or carcinoma during follow-up.
ContextSupports ESP as a benign lesion in most cases, though the low follow-up rate limits the certainty of this conclusion. Provides a pragmatic approach to managing ESP, addressing prior inconsistent reports of malignant potential.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Giovanis E … Zeki S · Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus · IF 2.5 · PubMed ↗Permalink
← Back to issue №19 Every section of this issue is one click away, at the top of this page. Follow Endoscopy by RSS